(Q59571933)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10958596%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

title

Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10958596%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

main subject

phase II clinical trial

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10958596%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Robert Motzer

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10958596%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

author name string

J Vuky

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10958596%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

J McCaffrey

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10958596%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

M Ginsberg

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10958596%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

T Mariani

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10958596%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

D F Bajorin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10958596%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

publication date

1 August 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10958596%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

9 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10958596%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10958596%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10958596%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

265-267

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10958596%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1023/a:1006434008357

9 November 2019

exact match

0 references

cites work

Testicular germ-cell cancer

1 reference

12 December 2020

Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor

1 reference

12 December 2020

The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent

1 reference

12 December 2020

Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.

1 reference

12 December 2020

Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro

1 reference

12 December 2020

Current status of pyrazoloacridine as an anticancer agent

1 reference

12 December 2020

Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival

1 reference

12 December 2020

High-dose chemotherapy for germ cell tumors (GCT): Memorial Sloan Kettering Cancer Center

1 reference

12 December 2020

Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934)

1 reference

12 December 2020